{"id":"W2169787227","doi":"10.1111/j.1365-2133.2006.07344.x","title":"CLinical experience acquired with the efalizumab (Raptiva<sup>®</sup>) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial","year":2006,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":143,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Efalizumab; Plaque psoriasis; Psoriasis; Placebo; Medicine; Randomized controlled trial; Clinical trial; Internal medicine; Dermatology; Alternative medicine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007700101,0.00136189,0.002951496,0.0002248902,0.0004968875,0.00113887,0.0009263486,0.001972081,0.003948838],"category_scores_gemma":[0.003660777,0.0006204989,0.001848958,0.00043324,0.001316968,0.001055822,0.0003707618,0.003308383,0.0008039055],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004946982,"about_ca_system_score_gemma":0.0009961511,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004593894,"about_ca_topic_score_gemma":0.0008579023,"domain_scores_codex":[0.9969642,0.002207109,0.0001983201,0.0002438316,0.0001883383,0.0001982231],"domain_scores_gemma":[0.9973078,0.0009633194,0.0007436399,0.0002205473,0.0001949541,0.0005697663],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9257553,0.01031566,0.003440042,0.001834043,0.001991731,0.00009796357,0.0001654737,0.0006591267,0.007425037,0.0002418243,0.002718117,0.0453556],"study_design_scores_gemma":[0.8783017,0.1115765,0.006416031,0.00008434003,0.0007690262,0.0001406128,0.0000269532,0.000238199,0.0005630202,0.0001293338,0.001736888,0.00001739363],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9472855,0.03598402,0.001539225,0.002192862,0.0004664574,0.00435046,0.001567988,0.000154363,0.006459117],"genre_scores_gemma":[0.9758075,0.009545682,0.00283974,0.00297642,0.0006993998,0.004253691,0.001950742,0.00003132538,0.001895495],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007700101,"threshold_uncertainty_score":0.04072249,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01187332646217483,"score_gpt":0.2591450540354009,"score_spread":0.2472717275732261,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}